Overview

A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection

Status:
Completed

Trial end date:
2000-03-01

Target enrollment:

Participant gender:

Summary

To assess the magnitude and duration of the antiviral activity in plasma and the incidence and time to total suppression of detectable HIV RNA in plasma. To assess the long-term safety and tolerability of this combination therapy and the magnitude and duration of the effect of this therapy over CD4 cell counts.

Phase:

N/A

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Didanosine
Hydroxyurea
Nelfinavir
Stavudine